Table 2.
Multivariate model output with estimates of the association of healthcare utilization with cohort members’ demographic, breast cancer, and treatment characteristics as well as BCRL status
| Variable | Coefficients | Robust S.E. |
Increase in utilization |
p | 95% confidence interval |
|
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Lymphedema | 0.27 | 0.03 | 31.0% | < .001 | 0.21 | 0.33 |
| Year since index | −0.02 | 0.003 | − 2.0% | < .001 | 0.01 | 0.03 |
| Axillary surgery* | ||||||
| Sentinel lymph node biopsy | 0.06 | 0.04 | 6.2% | 0.12 | − 0.02 | 0.14 |
| Complete axillary dissection | 0.05 | 0.04 | 5.1% | 0.17 | − 0.03 | 0.13 |
| Breast surgery† | ||||||
| Mastectomy | − 0.09 | 0.04 | − 8.6% | 0.03 | − 0.17 | − 0.01 |
| Mastectomy with contralateral prophylactic simple mastectomy | − 0.11 | 0.05 | − 10.5% | .02 | − 0.21 | − 0.01 |
| Male | 0.82 | 0.25 | 127.0% | 0.001 | 0.33 | 1.31 |
| Any hormone | − 0.09 | 0.03 | − 8.6% | <.001 | − 0.15 | − 0.03 |
| Any chemotherapy | 0.11 | 0.03 | 12.0% | 0.001 | 0.05 | 0.17 |
| Any radiation‡ | − 0.1 | 0.04 | − 9.6% | 0.01 | − 0.18 | − 0.02 |
| Calendar year of service | 0.005 | 0.003 | 0.5% | 0.12 | − 0.001 | 0.01 |
| Stage II§ | 0.16 | 0.03 | 17.4% | <.001 | 0.1 | 0.22 |
| Stage III§ | 0.39 | 0.06 | 47.7% | <.001 | 0.27 | 0.51 |
| Stage IV§ | 0.43 | 0.14 | 53.8% | 0.002 | 0.16 | 0.7 |
*
Control was “no axillary surgery”
†
Control was “lumpectomy or excisional biopsy”
‡
Control was “no radiation”
§
Control was “Stage B-I”